Artykuły w czasopismach na temat „JAK/STAT inhibitors”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „JAK/STAT inhibitors”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Jones, Dan, Justin Windham, Brian Stewart, Luis Fayad, Alma Rodriguez i Fredrick B. Hagemeister. "Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors." Blood 114, nr 22 (20.11.2009): 968. http://dx.doi.org/10.1182/blood.v114.22.968.968.
Pełny tekst źródłaMalemud, Charles J. "The role of the JAK/STAT signal pathway in rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease 10, nr 5-6 (19.05.2018): 117–27. http://dx.doi.org/10.1177/1759720x18776224.
Pełny tekst źródłaCacciapaglia, F., V. Venerito, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, N. Lacarpia, M. Fornaro i F. Iannone. "AB0070 INHIBITION OF STAT3 IN PBMCs FROM RHEUMATOID ARTHRITIS PATIENTS: CLUES TO UNDERSTAND SELECTIVITY OF JANUS KINASE INHIBITORS". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1167.2–1168. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1997.
Pełny tekst źródłaCacciapaglia, F., S. Perniola, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, M. Fornaro i F. Iannone. "AB0134 IN-VITRO STUDY ON THE EFFECT OF SELECTIVE Jak-INHIBITORS ON PBMCs STAT3 PHOSPHORYLATION FROM SYSTEMIC SCLEROSIS PATIENTS". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1196.3–1197. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2625.
Pełny tekst źródłaConzelmann, Michael, Elena Rodionova, Michael Hess, Thomas Giese, Anthony D. Ho, Peter Dreger i Thomas Luft. "Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells." Blood 110, nr 11 (16.11.2007): 2413. http://dx.doi.org/10.1182/blood.v110.11.2413.2413.
Pełny tekst źródłaGalli Sanchez, Ana Paula, Tatiane Ester Aidar Fernandes i Gustavo Martelli Palomino. "The JAK-STAT Pathway and the JAK Inhibitors". Journal of Clinical Research in Dermatology 7, nr 5 (30.11.2020): 1–6. http://dx.doi.org/10.15226/2378-1726/7/5/001128.
Pełny tekst źródłaRaivola, Juuli, Teemu Haikarainen, Bobin George Abraham i Olli Silvennoinen. "Janus Kinases in Leukemia". Cancers 13, nr 4 (14.02.2021): 800. http://dx.doi.org/10.3390/cancers13040800.
Pełny tekst źródłaRaivola, Juuli, Teemu Haikarainen i Olli Silvennoinen. "Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling". Cancers 12, nr 1 (27.12.2019): 78. http://dx.doi.org/10.3390/cancers12010078.
Pełny tekst źródłaBhagwat, Neha, Priya Koppikar, Outi Kilpivaara, Taghi Manshouri, Mazhar Adli, Ann Mullally, Omar Abdel-Wahab i in. "Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy". Blood 118, nr 21 (18.11.2011): 122. http://dx.doi.org/10.1182/blood.v118.21.122.122.
Pełny tekst źródłaMeyer, Sara C., Matthew D. Keller, Priya Koppikar, Olga A. Guryanova, Maria Kleppe, Anna Sophia McKenney, William R. Sellers i in. "Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models". Blood 124, nr 21 (6.12.2014): 160. http://dx.doi.org/10.1182/blood.v124.21.160.160.
Pełny tekst źródłaGorre, M., I. Jilani, H. Kantarjian, F. Giles, A. Hannah i M. Albitar. "Novel Quantitative Flow Cytometry-Based Signaling Assays Reveal a Potential Role for HSP90 Inhibitors in the Treatment of JAK2 Mutant-Positive Diseases." Blood 106, nr 11 (16.11.2005): 3526. http://dx.doi.org/10.1182/blood.v106.11.3526.3526.
Pełny tekst źródłaCallus, Bernard A., i Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, nr 9 (1.05.1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.
Pełny tekst źródłaCallus, Bernard A., i Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, nr 9 (1.05.1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.3182_3182_3192.
Pełny tekst źródłaHashemi, David, i Neal Bhatia. "The JAK-Cytokine Interface – A Review and Update on Prospective Clinical Considerations". SKIN The Journal of Cutaneous Medicine 7, nr 4 (17.07.2023): 932–35. http://dx.doi.org/10.25251/skin.7.4.16.
Pełny tekst źródłaShawky, Ahmed M., Faisal A. Almalki, Ashraf N. Abdalla, Ahmed H. Abdelazeem i Ahmed M. Gouda. "A Comprehensive Overview of Globally Approved JAK Inhibitors". Pharmaceutics 14, nr 5 (6.05.2022): 1001. http://dx.doi.org/10.3390/pharmaceutics14051001.
Pełny tekst źródłaMusumeci, Francesca, Chiara Greco, Ilaria Giacchello, Anna Lucia Fallacara, Munjed M. Ibrahim, Giancarlo Grossi, Chiara Brullo i Silvia Schenone. "An Update on JAK Inhibitors". Current Medicinal Chemistry 26, nr 10 (20.06.2019): 1806–32. http://dx.doi.org/10.2174/0929867325666180327093502.
Pełny tekst źródłaSuzuki, Asuka, Toshikatsu Hanada, Keiichi Mitsuyama, Takafumi Yoshida, Shintaro Kamizono, Tomoaki Hoshino, Masato Kubo i in. "Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation". Journal of Experimental Medicine 193, nr 4 (12.02.2001): 471–82. http://dx.doi.org/10.1084/jem.193.4.471.
Pełny tekst źródłaThomas, Sally J., Katherine Fisher, Stephen Brown, John A. Snowden, Sarah Danson i Martin Zeidler. "Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling". Blood 124, nr 21 (6.12.2014): 4577. http://dx.doi.org/10.1182/blood.v124.21.4577.4577.
Pełny tekst źródłaTaldaev, Amir, Vladimir R. Rudnev, Kirill S. Nikolsky, Liudmila I. Kulikova i Anna L. Kaysheva. "Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family". Pharmaceuticals 15, nr 1 (25.12.2021): 30. http://dx.doi.org/10.3390/ph15010030.
Pełny tekst źródłaMoser, Bernhard, Sophie Edtmayer, Agnieszka Witalisz-Siepracka i Dagmar Stoiber. "The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia". Biomedicines 9, nr 8 (19.08.2021): 1051. http://dx.doi.org/10.3390/biomedicines9081051.
Pełny tekst źródłaZhang, Xuekang, Jun Zhou, Qian Hu, Zhengren Liu, Qiuhong Chen, Wenxiang Wang, Huaigen Zhang, Qin Zhang i Yuanlu Huang. "The Role of Janus Kinase/Signal Transducer and Activator of Transcription Signalling on Preventing Intestinal Ischemia/Reperfusion Injury with Dexmedetomidine". Journal of Nanoscience and Nanotechnology 20, nr 5 (1.05.2020): 3295–302. http://dx.doi.org/10.1166/jnn.2020.16416.
Pełny tekst źródłaZheng, Ying, Hongwei Qin, Stuart J. Frank, Luqin Deng, David W. Litchfield, Ayalew Tefferi, Animesh Pardanani i in. "A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway". Blood 118, nr 1 (7.07.2011): 156–66. http://dx.doi.org/10.1182/blood-2010-01-266320.
Pełny tekst źródłaHu, Cheng-Ping, Jun-Tao Feng, Yu-Ling Tang, Jin-Qi Zhu, Min-Juan Lin i Ming-En Yu. "LIF Upregulates Expression of NK-1R in NHBE Cells". Mediators of Inflammation 2006 (2006): 1–8. http://dx.doi.org/10.1155/mi/2006/84829.
Pełny tekst źródłaKim, Jung Eun, Yu Jin Lee, Hye Ree Park, Dong Geon Lee, Kwan Ho Jeong i Hoon Kang. "The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells". International Journal of Molecular Sciences 21, nr 14 (20.07.2020): 5137. http://dx.doi.org/10.3390/ijms21145137.
Pełny tekst źródłaKarati, Dipanjan, Kakasaheb Ramoo Mahadik, Piyush Trivedi i Dileep Kumar. "The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer". Current Cancer Drug Targets 22, nr 3 (marzec 2022): 221–33. http://dx.doi.org/10.2174/1568009622666220301105214.
Pełny tekst źródłaKapuria, Vaibhav, Geoffrey Bartholomeusz, Ling-Yuan Kong, William Bornmann, Zhenghong Peng, Ashutosh Pal, David Maxwell, Moshe Talpaz i Nicholas Donato. "A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling." Blood 110, nr 11 (16.11.2007): 1556. http://dx.doi.org/10.1182/blood.v110.11.1556.1556.
Pełny tekst źródłaSpringuel, Lorraine, Tekla Hornakova, Elisabeth Losdyck, Fanny Lambert, Emilie Leroy, Stefan N. Constantinescu, Elisabetta Flex, Marco Tartaglia, Laurent Knoops i Jean-Christophe Renauld. "Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors". Blood 124, nr 26 (18.12.2014): 3924–31. http://dx.doi.org/10.1182/blood-2014-05-576652.
Pełny tekst źródłaSonkin, Dmitriy, Catherine Regnier, Xianhui Rong, Christie Fanton, Michael Palmer, Jocelyn Holash, Matthew Squires i in. "Identification of pSTAT5 gene signature in hematologic malignancy." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): 7111. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7111.
Pełny tekst źródłaHaysen, S., A. L. L. Nielsen, P. Qvist i T. W. Kragstrup. "POS0038 GENOMICS OF JAK-STAT SIGNALING IN VENOUS THROMBOEMBOLISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 234.1–234. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2593.
Pełny tekst źródłaJeong, Ga Hee, i Ji Hyun Lee. "Dysregulated Hippo Signaling Pathway and YAP Activation in Atopic Dermatitis: Insights from Clinical and Animal Studies". International Journal of Molecular Sciences 24, nr 24 (10.12.2023): 17322. http://dx.doi.org/10.3390/ijms242417322.
Pełny tekst źródłaPerner, Florian, Felix C. Saalfeld, Tina M. Schnoeder, Denise Wolleschak, Corinna Fahldieck, Satish Ranjan, Berend H. Isermann i in. "Specificity of JAK-Kinase Inhibition Determines Impact on T-Cell Function". Blood 124, nr 21 (6.12.2014): 1410. http://dx.doi.org/10.1182/blood.v124.21.1410.1410.
Pełny tekst źródłaPurandare, Ashok V., Animesh Pardanani, Theresa McDevitt, Marco Gottardis, Terra Lasho, Dan You, Louis Lombardo i in. "Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2". Blood 116, nr 21 (19.11.2010): 4112. http://dx.doi.org/10.1182/blood.v116.21.4112.4112.
Pełny tekst źródłaLim, Ken-Hong, Yu-Cheng Chang, Yi-Hao Chiang, Huan-Chau Lin, Ling Huang, Wei-Ting Wang, Ying-Wen Su, Ming-Chih Chang, Yi-Fang Chang i Caleb Gon-Shen Chen. "Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms". Blood 134, Supplement_1 (13.11.2019): 2970. http://dx.doi.org/10.1182/blood-2019-124420.
Pełny tekst źródłaRodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, John Weroha i John Hawse. "Abstract 1129: Interrogating JAK/STAT signaling in ovarian cancer as a potential oncogenic driver and therapeutic target". Cancer Research 82, nr 12_Supplement (15.06.2022): 1129. http://dx.doi.org/10.1158/1538-7445.am2022-1129.
Pełny tekst źródłaClarke, A., J. Di Paolo, B. Downie, A. Meng, N. Mollova, Y. Yu i P. Han. "P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis". Journal of Crohn's and Colitis 14, Supplement_1 (styczeń 2020): S409. http://dx.doi.org/10.1093/ecco-jcc/jjz203.589.
Pełny tekst źródłaRoss, David M., Jeffrey J. Babon, Denis Tvorogov i Daniel Thomas. "Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications". Haematologica 106, nr 5 (21.01.2021): 1244–53. http://dx.doi.org/10.3324/haematol.2020.262691.
Pełny tekst źródłaMontero, Paula, Javier Milara, Inés Roger i Julio Cortijo. "Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms". International Journal of Molecular Sciences 22, nr 12 (9.06.2021): 6211. http://dx.doi.org/10.3390/ijms22126211.
Pełny tekst źródłaBanes, Amy K., Séan Shaw, John Jenkins, Heather Redd, Farhad Amiri, David M. Pollock i Mario B. Marrero. "Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli". American Journal of Physiology-Renal Physiology 286, nr 4 (kwiecień 2004): F653—F659. http://dx.doi.org/10.1152/ajprenal.00163.2003.
Pełny tekst źródłaJang, Sun Hee, i Ji Hyeon Ju. "Janus kinase inhibitors for the treatment of rheumatoid arthritis". Journal of the Korean Medical Association 64, nr 2 (10.02.2021): 105–8. http://dx.doi.org/10.5124/jkma.2021.64.2.105.
Pełny tekst źródłaSimon, Amy R., Satoe Takahashi, Mariano Severgnini, Barry L. Fanburg i Brent H. Cochran. "Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells". American Journal of Physiology-Lung Cellular and Molecular Physiology 282, nr 6 (1.06.2002): L1296—L1304. http://dx.doi.org/10.1152/ajplung.00315.2001.
Pełny tekst źródłaLiu, Liqin, Violeta Yu, Jeanne Pistillo, Josie Lee, Laurie B. Schenkel, Stephanie Geuns-Meyer, Ivonne Archibeque, Angus Sinclair, Renee Emkey i Graham Molineux. "New Insights on Assessing Intra-Family Selectivity for Jak2 Inhibitors". Blood 118, nr 21 (18.11.2011): 5150. http://dx.doi.org/10.1182/blood.v118.21.5150.5150.
Pełny tekst źródłaPérez, Cristina, Julia Gonzalez-Rincon, Carmen Almaraz, Soraya Curiel, Nuria Garcia, Helena Pisonero, Sagrario Gomez i in. "A Role of JAK/STAT Pathway in Cutaneous T-Cell Lymphomas: Exploring Its Effects for Targeted Therapy". Blood 124, nr 21 (6.12.2014): 4498. http://dx.doi.org/10.1182/blood.v124.21.4498.4498.
Pełny tekst źródłaHindupur, Sruthi V., Sebastian C. Schmid, Jana Annika Koch, Ahmed Youssef, Eva-Maria Baur, Dongbiao Wang, Thomas Horn i in. "STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy". International Journal of Molecular Sciences 21, nr 3 (7.02.2020): 1106. http://dx.doi.org/10.3390/ijms21031106.
Pełny tekst źródłaBarton, Beverly E., James G. Karras, Thomas F. Murphy, Arnold Barton i Hosea F.-S. Huang. "Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines". Molecular Cancer Therapeutics 3, nr 1 (1.01.2004): 11–20. http://dx.doi.org/10.1158/1535-7163.11.3.1.
Pełny tekst źródłaWestfall, Matt, Rachael E. Hawtin, Diane Longo, Michelle Cholankeril, Reena K. Vora, Michelle Atallah, Alessandra Cesano, Steven L. Allen i Scott Z. Fields. "Functional Pathway Analysis Of JAK2 Mutated and Wild Type Myeloproliferative Neoplasms As a Tool For Patient Stratification and Therapeutic Selection". Blood 122, nr 21 (15.11.2013): 5263. http://dx.doi.org/10.1182/blood.v122.21.5263.5263.
Pełny tekst źródłaFujita, M., K. Fukuda, S. Hayashi, K. Kikuchi, Y. Takashima, T. Kamenaga, T. Maeda, T. Matsubara i R. Kuroda. "AB0089 THE ANALYSIS FOR THE INHIBITION OF ANGIOGENESIS BY JAK INHIBITOR". Annals of the Rheumatic Diseases 79, Suppl 1 (czerwiec 2020): 1344.2–1344. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3161.
Pełny tekst źródłaSeverin, Frezzato, Visentin, Martini, Trimarco, Carraro, Tibaldi i in. "In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment". Cancers 11, nr 12 (4.12.2019): 1939. http://dx.doi.org/10.3390/cancers11121939.
Pełny tekst źródłaChen, Jing, Yong Zhang, Michael N. Petrus, Wenming Xiao, Alina Nicolae, Mark Raffeld, Stefania Pittaluga i in. "Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations". Proceedings of the National Academy of Sciences 114, nr 15 (29.03.2017): 3975–80. http://dx.doi.org/10.1073/pnas.1700682114.
Pełny tekst źródłaVian, Laura, Mimi Lee, Giuseppe Sciumè, Nathalia Gazaniga, Stefania Dell'Orso, Stephen Brooks i Massimo Gadina. "Elucidating the role of cytokine signaling in the homeostasis of innate immune cells with JAK inhibitors". Journal of Immunology 202, nr 1_Supplement (1.05.2019): 181.27. http://dx.doi.org/10.4049/jimmunol.202.supp.181.27.
Pełny tekst źródłaHan, Yaguang, Yan Zhang, Ying Tian, Miao Zhang, Cheng Xiang, Qiang Zhen, Jiabao Liu i in. "The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells". Journal of Oncology 2022 (21.09.2022): 1–16. http://dx.doi.org/10.1155/2022/9016296.
Pełny tekst źródła